Advanced Therapy in EpilepsyA comprehensive and up-to-date primer on the latest therapeutic advances in the management and treatment of epilepsy, this work includes practical information on diagnostic criteria for all different syndromes along with detailed discussions of appropriate agents. |
Contents
1 | |
2 | |
8 | |
16 | |
23 | |
27 | |
37 | |
Neuroimaging in Epilepsy | 45 |
Principles of Pharmacokinetics and Pharmacogenetics of Anticonvulsants | 242 |
Pregnancy Epilepsy and Drug Treatment | 255 |
Epileptic Drug Treatment in Special Populations | 262 |
Systemic Metabolic Consequences of Antiepileptic Medication | 271 |
Barbiturates | 277 |
Benzodiazepines | 284 |
Carbamazepine and Oxcarbazepine | 291 |
Ethosuximide | 296 |
Experimental Models of Seizures and Epilepsy | 53 |
The EEG of Epilepsy | 57 |
Genetic and Chromosomal Disorders in Epilepsy | 67 |
Neuropathology of Pediatric Cerebral Resections for Epilepsy | 77 |
Neurometabolic Disorders and Epilepsy | 92 |
Neurocutaneous Disorders and Epilepsy | 99 |
Neonatal Seizures | 108 |
Epilepsy in Developmental Disorders | 117 |
Epilepsy in Neurodegenerative Diseases | 126 |
Acquired Lesions and Epilepsy | 132 |
Febrile Seizures | 136 |
Convulsive Status Epilepticus | 144 |
Clinical Features Diagnosis and Treatment of nonconvulsive Status Epilepticus | 152 |
Temporal Lobe Epilepsy Syndromes | 157 |
PartialOnset Seizures and LocalizationRelated Epilepsy Syndromes | 165 |
Generalized Seizures and Generalized Epilepsy Syndromes | 179 |
LandauKleffner Syndrome and Language Dysfunction in Epilepsy | 199 |
Rasmussen Encephalitis | 208 |
Nonepileptic Paroxysmal Disorders | 213 |
Psychogenic Nonepileptic Seizures | 220 |
Neurotransmitters and Drug Development in Epilepsy | 226 |
Antiepileptic Drugs An Overview | 234 |
Gabapentin and Pregabalin | 302 |
Lamotrigine | 313 |
Levetiracetam | 320 |
Phenytoin and Fosphenytoin | 326 |
Topiramate | 336 |
Valproic Acid | 343 |
Vigabatrin | 349 |
Zonisamide | 355 |
Other Antiepileptic Drugs | 361 |
Use of Antidepressants in Epilepsy What All Neurologists Should Know | 370 |
Immunotherapy in Epilepsy | 377 |
Dietary Therapy for Epilepsy | 386 |
Neurostimulation Therapy for Epilepsy | 393 |
Epilepsy Surgery | 402 |
Prognosis and Ongoing Management of Epilepsy | 415 |
Neuropsychiatry Comorbidities with Epilepsy in Children and Adolescents | 423 |
Epilepsy and Cognition | 430 |
Practical Treatment Strategies of Psychiatric Comorbidities in Adults with Epilepsy | 437 |
Therapeutic Uses of Seizures in Neuropsychiatry | 448 |
Social Challenges Among Children and Adolescents with Intractable Epilepsy | 453 |
Monitoring for Adverse Effects of Antiepileptic Drugs | 460 |
Common terms and phrases
abnormalities absence epilepsy absence seizures ACTH activity adolescents adults adverse effects anticonvulsant antiepileptic drugs associated behavior benign benzodiazepines brain carbamazepine cerebral childhood clinical cognitive complex partial concentration convulsive status epilepticus cortex cortical depression diagnosis diazepam discharges disease disorders dose double-blind efficacy electrodes epilepsy surgery epilepsy syndromes epileptic epileptiform ethosuximide febrile seizures focal frequent frontal GABA gabapentin genetic hepatic ictal idiopathic increased infantile spasms inhibitors interictal intravenous lamotrigine Landau-Kleffner syndrome lesions levels levetiracetam medication metabolism mg/d mg/kg/d monotherapy Neurology neurons normal occur onset oxcarbazepine partial epilepsy partial seizures patients with epilepsy pediatric pharmacokinetics phenobarbital phenytoin placebo plasma pregabalin primidone protein psychogenic nonepileptic seizures receptors recurrence refractory renal reported resection risk seizure control seizure free seizure frequency seizure types serum side effects spike-wave spikes studies symptoms temporal lobe epilepsy therapy tion tonic tonic-clonic seizures topiramate treatment trials vagus nerve stimulator valproate valproic acid vigabatrin zonisamide